DNA aneuploidy in relation to the combination of analysis of estrogen receptor, progesterone receptor, p53 protein and epidermal growth factor receptor in 498 breast cancers

Oncology

Volumn 63, Issue 1, 2002, Pages 48-55

  Tsutsui, Shinichi ^a   Ohno, Shinji ^b   Murakami, Shigeru ^b   Hachitanda, Yoichi ^b   Oda, Shinya ^b  

^a NATIONAL HOSPITAL ORGANIZATION BEPPU MEDICAL CENTER   (Japan)

^b NATIONAL KYUSHU CANCER CENTER   (Japan)

Author keywords

Breast cancer; DNA ploidy; Epidermal growth factor receptor; Estrogen receptor; p53 protein; Progesterone receptor

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P53;

ADULT; AGED; ANEUPLOIDY; ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA DETERMINATION; ENZYME IMMUNOASSAY; FEMALE; FLOW CYTOMETRY; FREEZING; GENETIC HETEROGENEITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INCIDENCE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PLOIDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEFICIENCY; RISK; TREATMENT PLANNING;

ADULT; AGED; AGED, 80 AND OVER; ANEUPLOIDY; BREAST NEOPLASMS; DNA, NEOPLASM; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MULTIVARIATE ANALYSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036355759     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000065720     Document Type: Article

References (37)

1. Significance of aneuploidy
2. A flow cytometric analysis of DNA content in primary and metastatic lesions of esophageal squamous cell carcinoma
3. Flow cytometric DNA analysis is useful in detecting multiple genetic alterations in squamous cell carcinoma of the esophagus
4. Origins and clinical implications of aneuploidy in early bladder cancer
5. Prognostic value of DNA ploidy in 653 Japanese women with node-negative breast cancer
6. Relationship between ploidy and steroid hormone receptors in primary invasive breast cancer
7. Flow cytometry of breast carcinoma. 1. Relation of DNA ploidy level to histology and estrogen receptor
8. DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients
9. Cell cycle analysis of 932 flow cytometric DNA histograms of fresh frozen breast carcinoma material. Correlations between flow cytometric, clinical, and pathologic variables
10. Relationship of DNA ploidy to hormone receptor status and proliferation in invasive breast carcinoma
11. Cytometric DNA analysis and prognostic biomarkers in breast carcinoma. Expression of p53 product in the different ploidy classes
12. p53 gene mutations and expression of p53 and mdm2 proteins in invasive breast carcinoma. A comparative analysis with clinico-pathological factors
13. Abnormal p53 immunoreactivity and prognosis in node-negative breast carcinomas with long-term follow-up
14. p53 as a prognostic factor in stage I breast cancer
15. DNA content and p53 protein expression in ductal breast cancer
16. DNA flow cytometry of human breast carcinomas and its relationship to transferrin and epidermal growth factor receptors
17. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: A review on 5232 patients
18. Evaluation of flow-cytometric three-parameter analysis for EGFR quantification and DNA assessment in human bladder carcinomas
19. Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer
20. ERBB2 oncogene in human breast cancer and its clinical significance
21. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis
22. Prognostic value of p53 protein expression in breast cancer; an immunohistochemical analysis of frozen sections in 514 Japanese women
23. Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer
24. Human breast cancer: Prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features
25. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for short term prognosis in breast cancer
26. Correlation between p53, c-erbB-2, and topoisomerase IIα expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: Prognostic implications
27. Immunohistochemical expression of p53, nm23-HI, Ki67 and DNA ploidy: Correlation with lymph node status and other clinical pathologic parameters in breast cancer
28. Tubular carcinoma of the breast: Immunohistochemical and DNA flow cytometric profile
29. Breast cancer genetic evolution. 1. Data from cytogenetics and DNA content
30. Comparative genomic hybridization of formalin-fixed, paraffin-embedded breast tumors reveals different patterns of chromosomal gains and losses in fibroadenomas and diploid and aneuploid carcinomas
31. Genetic evolution of breast cancer. 2. Relationship with estrogen and progesterone receptor expression
32. In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice
33. Genetic alterations on chromosome 17 in human breast cancer: Relationships to clinical features and DNA ploidy
34. Loss of heterozygosity on the short arm of chromosome 17 is associated with high proliferative capacity and DNA aneuploidy in primary human breast cancer
35. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology
36. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy
37. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients